| Old Articles: <Older 7571-7580 Newer> |
|---|
 |
The Motley Fool
June 24, 2011
Jordan DiPietro |
Should You Buy and Hold Sanofi? Sanofi has a beta of 0.7, which is pretty low. Generally speaking, I like to see a beta below 1.2 for retirees. In this case, Sanofi fits the bill.   |
The Motley Fool
June 24, 2011
Arundhati Parmar |
Data on St. Jude Migraine Treatment "Impressive" An effective migraine treatment would be very valuable for St. Jude. |
BusinessWeek
June 23, 2011
Naomi Kresge |
Bayer Aspirin Is Feeling Plenty Healthy While J&J's Tylenol recovers from a recall, sales of century-old Bayer are soaring. |
BusinessWeek
June 23, 2011
Drew Armstrong |
The Simplest Rx: Check on Your Patient Doctors and insurers cut costs by sharing information. |
The Motley Fool
June 23, 2011
Brian Orelli |
In Addition, Our Drug Actually Rocks Pfizer and Bristol get good data on Eliquis. |
The Motley Fool
June 23, 2011
Brian Orelli |
One Less Oral MS Drug to Worry About But competition is still tough. |
Chemistry World
June 22, 2011
Sarah Houlton |
US Approves Cancer Drugs Twice as Fast as Europe Cancer drugs are, on average, approved nearly twice as fast in the US than they are in Europe. |
The Motley Fool
June 22, 2011
Brian Orelli |
Building on Pfizer's Blockbuster New data for an expanded indication for Lyrica. |
The Motley Fool
June 22, 2011
Brian Orelli |
In-Licensing to the Rescue Abbott's latest deal could help shore things up. |
The Motley Fool
June 22, 2011
Seth Jayson |
Why Abbott Laboratories May Be About to Take Off Abbott Laboratories may display positive inventory divergence, suggesting that management sees increased demand on the horizon. |
| <Older 7571-7580 Newer> Return to current articles. |
